Clinical Trials Browser

Phase 1 × tazemetostat × 1 year × Clear all

NCT05353439 2026-03-18

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT05627245 2026-03-18

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1 Active not recruiting

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06824701 2025-12-03

TARZAN

Phase 1 Recruiting

Recurrence, Lymphoma, B-Cell

NCT05983965 2025-09-10

Study of Tazemetostat in Lymphoid Malignancies

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, T-Cell

NCT05934838 2025-08-15

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Phase 1 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04846478 2025-04-17

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05618366 2025-04-08

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse